中国实用神经疾病杂志
中國實用神經疾病雜誌
중국실용신경질병잡지
CHINESE JOURNAL OF PRACTICAL NERVOUS DISEASES
2015年
18期
4-6
,共3页
刘艳%刘文鹏%魏灿%张艳荣%丁云龙
劉豔%劉文鵬%魏燦%張豔榮%丁雲龍
류염%류문붕%위찬%장염영%정운룡
氯吡格雷%低分子肝素%阿司匹林%短暂性脑缺血发作
氯吡格雷%低分子肝素%阿司匹林%短暫性腦缺血髮作
록필격뢰%저분자간소%아사필림%단잠성뇌결혈발작
Clopidogrel%Low-molecular-weight heparin%Aspirin%Transient ischemic attack
目的:探讨氯吡格雷联合阿司匹林与低分子肝素联合阿司匹林治疗短暂性脑缺血发作(transient ischemic at‐tack ,TIA)的疗效。方法收集入院治疗的102例TIA患者,按ABCD3‐I评分法分为低(<4)、中高危(≥4)2组,每组再随机分为双抗(氯吡格雷+阿司匹林)组和抗凝(低分子肝素+阿司匹林)组。观察7 d内2组 T IA控制率,记录不良反应,随访1个月。结果低危组的双抗组有效率(97.6%)略高于抗凝组(95.1%,P=0.556);中高危组的抗凝组有效率(90.0%)高于双抗组(80.0%),差异无统计学意义(P>0.05)。双抗组不良反应均低于抗凝组,差异无统计学意义(P>0.05)。结论对AB‐CD3‐I评分≤4的低危患者优先选择氯吡格雷联合阿司匹林治疗,对ABCD3‐I评分≥4的中高危患者,低分子肝素联合阿司匹林的近期疗效可能优于氯吡格雷联合阿司匹林。
目的:探討氯吡格雷聯閤阿司匹林與低分子肝素聯閤阿司匹林治療短暫性腦缺血髮作(transient ischemic at‐tack ,TIA)的療效。方法收集入院治療的102例TIA患者,按ABCD3‐I評分法分為低(<4)、中高危(≥4)2組,每組再隨機分為雙抗(氯吡格雷+阿司匹林)組和抗凝(低分子肝素+阿司匹林)組。觀察7 d內2組 T IA控製率,記錄不良反應,隨訪1箇月。結果低危組的雙抗組有效率(97.6%)略高于抗凝組(95.1%,P=0.556);中高危組的抗凝組有效率(90.0%)高于雙抗組(80.0%),差異無統計學意義(P>0.05)。雙抗組不良反應均低于抗凝組,差異無統計學意義(P>0.05)。結論對AB‐CD3‐I評分≤4的低危患者優先選擇氯吡格雷聯閤阿司匹林治療,對ABCD3‐I評分≥4的中高危患者,低分子肝素聯閤阿司匹林的近期療效可能優于氯吡格雷聯閤阿司匹林。
목적:탐토록필격뢰연합아사필림여저분자간소연합아사필림치료단잠성뇌결혈발작(transient ischemic at‐tack ,TIA)적료효。방법수집입원치료적102례TIA환자,안ABCD3‐I평분법분위저(<4)、중고위(≥4)2조,매조재수궤분위쌍항(록필격뢰+아사필림)조화항응(저분자간소+아사필림)조。관찰7 d내2조 T IA공제솔,기록불량반응,수방1개월。결과저위조적쌍항조유효솔(97.6%)략고우항응조(95.1%,P=0.556);중고위조적항응조유효솔(90.0%)고우쌍항조(80.0%),차이무통계학의의(P>0.05)。쌍항조불량반응균저우항응조,차이무통계학의의(P>0.05)。결론대AB‐CD3‐I평분≤4적저위환자우선선택록필격뢰연합아사필림치료,대ABCD3‐I평분≥4적중고위환자,저분자간소연합아사필림적근기료효가능우우록필격뢰연합아사필림。
Objective To compare the clinical efficacy of clopidogrel and aspirin(ASA) versus low‐molecular‐weight hepa‐rin(LMWH) and aspirin in patients with transient ischemic attack(TIA) .Methods 102 cases with TIA were classified into two groups according to the ABCD3‐I scores:low risk group (ABCD3‐I <4 scores) and moderate‐high risk group(ABCD3‐I ≥4 scores) .Furthermore ,two groups were randomly divided into ASA subgroup ( clopidogrel and aspirin ) and LMWH subgroup (low‐molecular‐weight heparin and aspirin ) .We recorded control rate to assess therapeutic effect and presented adverse events within 7‐day treatment ,and kept 1‐month follow‐up .Results In low risk group ,the control rate in ASA subgroup (97 .6% ) was slightly higher than that in LMWH subgroup (95 .1% ) .And conversely ,in moderate‐high risk group ,LMWH subgroup (90 .0% ) obtained the higher control rate than ASA subgroup (80 .0% ) with no statistical difference .Although the adverse e‐vents in ADR subgroup were less than that in LMWH subgroup ,there was no significant difference in terms of incidence .Con‐clusion The present study demonstrates that low risk patients with ABCD3‐I <4 scores should consider the therapy of clopi‐dogrel and aspirin as first choice ,and as for moderate‐high risk patients with ABCD3‐I ≥4 scores ,low‐molecular‐weight hepa‐rin and aspirin maybe has better short‐time efficacy than clopidogrel and aspirin .